论文部分内容阅读
目的对比埃克替尼与厄洛替尼应用于晚期非小细胞肺癌中的临床疗效。方法 84例晚期非小细胞肺癌患者,随机分为对照组与观察组,各42例。对照组给予患者口服厄洛替尼,观察组给予患者口服埃克替尼,比较两组患者治疗效果与不良反应发生情况。结果两组患者疾病控制率、总缓解率及中位肿瘤进展时间比较差异均无统计学意义(P>0.05);观察组患者的总不良反应发生率为47.6%,显著低于对照组71.4%,差异有统计学意义(P<0.05)。结论埃克替尼与厄洛替尼对晚期非小细胞肺癌有相似疗效,相对于厄洛替尼而言,埃克替尼治疗晚期非小细胞肺癌具有较低的不良反应发生率,具有临床借鉴意义。
Objective To compare the clinical efficacy of icotinib and erlotinib in advanced non-small cell lung cancer. Methods Eighty-four patients with advanced non-small cell lung cancer were randomly divided into control group and observation group, with 42 cases in each group. Patients in the control group were given oral erlotinib, while those in the observation group were given imatinib orally. The therapeutic effect and adverse reactions of the two groups were compared. Results There was no significant difference in disease control rate, total remission rate and median tumor progression time between the two groups (P> 0.05). The incidence of adverse reactions in the observation group was 47.6%, which was significantly lower than that in the control group (71.4% , The difference was statistically significant (P <0.05). Conclusions Icutinib and erlotinib have similar curative effect on advanced non-small cell lung cancer. Compared with erlotinib, Icitinib has a lower incidence of adverse reactions in advanced non-small cell lung cancer, Reference meaning.